ASEP Medical Holdings Inc. Stock OTC Markets

Equities

SEPSF

CA04368A1057

Biotechnology & Medical Research

Market Closed - OTC Markets 01:09:23 2024-06-27 pm EDT 5-day change 1st Jan Change
0.1 USD +100.00% Intraday chart for ASEP Medical Holdings Inc. +100.00% -43.41%
Sales 2022 - Sales 2023 21.14K 15.44K Capitalization 14.4M 10.52M
Net income 2022 -4M -2.92M Net income 2023 -8M -5.84M EV / Sales 2022 -
Net cash position 2022 3.28M 2.4M Net cash position 2023 205K 150K EV / Sales 2023 672 x
P/E ratio 2022
-7.95 x
P/E ratio 2023
-1.55 x
Employees 7
Yield 2022 *
-
Yield 2023
-
Free-Float 96.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day+100.00%
1 week+100.00%
Current month+100.00%
1 month+100.00%
3 months+100.00%
6 months-43.41%
Current year-43.41%
More quotes
1 week
0.10
Extreme 0.1
0.10
1 month
0.10
Extreme 0.1
0.10
Current year
0.05
Extreme 0.05
0.15
1 year
0.05
Extreme 0.05
0.50
3 years
0.05
Extreme 0.05
0.50
5 years
0.05
Extreme 0.05
0.50
10 years
0.05
Extreme 0.05
0.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 75 21-01-19
Director of Finance/CFO 68 22-09-30
Chief Tech/Sci/R&D Officer - 23-02-23
Members of the board TitleAgeSince
Chief Executive Officer 75 21-01-19
Director/Board Member 62 21-11-08
Chief Operating Officer 53 21-11-08
More insiders
Date Price Change Volume

Delayed Quote OTC Markets, June 27, 2024 at 01:09 pm EDT

More quotes
ASEP Medical Holdings Inc. is a Canada-based company, which is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. The Company’s consolidates three development-stage companies, including Sepset Biosciences Inc., ABT Innovations Inc., and SafeCoat Medical Inc. It provides medical devices with an anti-microbial, antifouling coating through its SafeCoat Medical Inc. The Company also provides diagnostic kits for predicting the onset of severe Sepsis and organ failure through its Sepset Biosciences Inc. The Company also offers peptide technology through its ABT Innovations Inc. Its technology includes diagnostic and therapeutic. It has developed a novel diagnostic assay for the early and rapid diagnosis of sepsis, based on the detection of molecular signatures of sepsis specific to the immune response, rather than the presence of a pathogen.
More about the company